Response to Ra-223-dichloride in castration-resistant prostate cancer with bone metastasis: A case report
Por:
Cabrera, ME, Rey, PM, Carrio, I, Montes, A, Lopez, DA
Publicada:
1 ago 2016
Resumen:
Painful bone metastases are common in prostate cancer, with current treatments including non-steroidal analgesics and opiates, surgery, external beam radiotherapy and bone-targeting beta-emitting radiopharmaceuticals. The a-emitting isotope Ra-223-dichloride (Ra-223) has been associated with improved overall survival and increased time to first skeletal-related events in patients with castration-resistant prostate cancer (CRPC) presenting with symptomatic bone metastases. The current study reports the case of a 70-year-old male patient, who was diagnosed with prostate cancer in 1999 upon presentation with increased prostate-specific antigen (PSA) levels and painful bone metastases in the context of CRPC. In November 2010, subsequent to undergoing hormonal blockage, the patient was treated with ketoconazole (200 mg/8 h) followed by 10 cycles of docetaxel (75 mg/m(2) every 3 weeks). Following disease progression, the patient received 6 doses of Ra-223 (50 kBq/kg; 1 dose/4 weeks). During this treatment period, an improvement in the patient's symptoms, and levels of bone alkaline phosphatase (BAP) and PSA were noted. Furthermore, Ra-223 was well-tolerated without any relevant bone marrow toxicity. However, 2 months after the administration of the final dose of Ra-223, PSA and BAP levels increased again, and bone pain deteriorated. A bone scan showed stable disease in the previously observed metastatic lesions; however, new lesions simultaneously appeared in different locations, indicating progressive disease.
Filiaciones:
Cabrera, ME:
Autonomous Univ Barcelona, Hosp Santa Creu & St Pau, Dept Nucl Med, 167 Carrer St Antoni Maria Claret, Barcelona 08025, Spain
Rey, PM:
Autonomous Univ Barcelona, Hosp Santa Creu & St Pau, Dept Med Oncol, Barcelona 08025, Spain
Carrio, I:
Autonomous Univ Barcelona, Hosp Santa Creu & St Pau, Dept Nucl Med, 167 Carrer St Antoni Maria Claret, Barcelona 08025, Spain
Montes, A:
Autonomous Univ Barcelona, Hosp Santa Creu & St Pau, Dept Nucl Med, 167 Carrer St Antoni Maria Claret, Barcelona 08025, Spain
Lopez, DA:
Autonomous Univ Barcelona, Hosp Santa Creu & St Pau, Dept Nucl Med, 167 Carrer St Antoni Maria Claret, Barcelona 08025, Spain
Green Published, Hybrid Gold
|